Indicators that determine disease course in COVID-19 patients

In this study, it was tried to determine the factors affecting the clinical process in patients who were followed up in hospital for coronavirus disease-2019 (COVID-19).

The study, which was designed as a single-center and retrospective cohort, included 658 patients admitted to the service due to COVID-19. The patients were grouped and compared as the patients followed up in the wards (Group 1) and those admitted to ICU (Group 2), between those who were intubated (Group I) in the ICU and those who were not (Group NI), and between patient groups who died (Group M) and survived (Group NM) among those who were intubated.

Of the 658 patients hospitalized in the wards, 566 (86%) were discharged and 99 (14%) were later admitted to the ICU. The mortality rate for the 658 patients that were followed up was found to be 7.75%. When Groups 1 and 2 were compared, it was observed that the patients in Group 2 had more comorbidity and higher KDIGO stages (p<0.001). In addition, patients in Group 2 had older age, higher APACHE II and SOFA scores, high WBC counts, neutrophil counts, lymphocyte counts, N/L ratio, CRP, LDH, CK, PTZ, D-dimer, procalcitonin, and ferritin values (all values p<0.001, for CK p=0.034). When the patients in Group I and Group NI were compared, it was observed that the patients in Group I had more comorbidities and higher mortality rate (p<0.001). In addition, patients in Group I had older age, high D-dimer, and ferritin levels (p=0.008; 0.011, and 0.043, respectively). When the patients in Group M and Group NM were compared, it was observed that the patients in Group M were mostly males (p=0.017) and were mostly in KDIGO Stages 1 and 2 (p=0.005). In addition, it was found that the CRP and LDH levels of patients in Group M were significantly higher than those in Group NM (p=0.018 and 0.023, respectively).

Comorbidity, clinical features, and laboratory findings are parameters that can help in predicting the clinical course of hospitalized patients due to COVID-19.